GC Biopharma Corp. (KRX:006280)
124,900
-2,500 (-1.96%)
At close: Mar 28, 2025, 3:30 PM KST
GC Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Net Income | -26,280 | -26,632 | 65,453 | 123,212 | 81,049 | Upgrade
|
Depreciation & Amortization | 81,034 | 75,899 | 65,096 | 55,904 | 48,791 | Upgrade
|
Loss (Gain) From Sale of Assets | 2,511 | 2,919 | -40,657 | -6,991 | -59,361 | Upgrade
|
Asset Writedown & Restructuring Costs | 18,088 | - | - | - | 8,140 | Upgrade
|
Loss (Gain) From Sale of Investments | -6,665 | -1,209 | 660 | 333 | -36,673 | Upgrade
|
Loss (Gain) on Equity Investments | 27,464 | 38,431 | 18,099 | -81,533 | 5,635 | Upgrade
|
Provision & Write-off of Bad Debts | 1,079 | 2,789 | 2,246 | 6,980 | 336 | Upgrade
|
Other Operating Activities | -6,594 | 2,649 | 17,119 | 47,052 | 69,970 | Upgrade
|
Change in Accounts Receivable | 52,815 | -47,093 | 13,219 | -10,756 | -16,862 | Upgrade
|
Change in Inventory | -229,626 | -69,234 | 1,721 | -14,919 | -52,086 | Upgrade
|
Change in Accounts Payable | 12,077 | 22,689 | 4,011 | -16,463 | -3,906 | Upgrade
|
Change in Other Net Operating Assets | 20,637 | -6,681 | -27,813 | 23,160 | -9,059 | Upgrade
|
Operating Cash Flow | -53,460 | -5,473 | 119,154 | 125,979 | 35,974 | Upgrade
|
Operating Cash Flow Growth | - | - | -5.42% | 250.20% | -10.72% | Upgrade
|
Capital Expenditures | -31,992 | -79,087 | -57,996 | -102,321 | -82,876 | Upgrade
|
Sale of Property, Plant & Equipment | 791.34 | 1,319 | 1,540 | 565.21 | 236.6 | Upgrade
|
Cash Acquisitions | - | - | -74,053 | 11,918 | -1,582 | Upgrade
|
Divestitures | 215.13 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -9,602 | -45,914 | -36,694 | -21,143 | -18,345 | Upgrade
|
Investment in Securities | -24,226 | -25,139 | -31,332 | -30,734 | 24,393 | Upgrade
|
Other Investing Activities | 2,269 | -1,423 | -723.7 | 10,133 | 107,856 | Upgrade
|
Investing Cash Flow | -67,894 | -150,243 | -205,259 | -132,077 | 29,684 | Upgrade
|
Short-Term Debt Issued | 1,221,140 | 1,188,247 | 806,151 | 869,500 | 1,044,670 | Upgrade
|
Long-Term Debt Issued | 279,387 | 5,000 | 30,608 | 209,429 | 23,800 | Upgrade
|
Total Debt Issued | 1,500,527 | 1,193,247 | 836,759 | 1,078,929 | 1,068,470 | Upgrade
|
Short-Term Debt Repaid | -1,169,646 | -1,059,800 | -721,740 | -992,600 | -885,603 | Upgrade
|
Long-Term Debt Repaid | -217,342 | -9,419 | -135,590 | -102,423 | -100,486 | Upgrade
|
Total Debt Repaid | -1,386,988 | -1,069,219 | -857,330 | -1,095,023 | -986,088 | Upgrade
|
Net Debt Issued (Repaid) | 113,538 | 124,028 | -20,571 | -16,094 | 82,382 | Upgrade
|
Dividends Paid | -19,532 | -24,825 | -23,985 | -18,511 | -12,719 | Upgrade
|
Other Financing Activities | -160.89 | 1,308 | 42,075 | -6,665 | 11,325 | Upgrade
|
Financing Cash Flow | 93,845 | 100,512 | -2,481 | -41,270 | 80,987 | Upgrade
|
Foreign Exchange Rate Adjustments | 366.22 | -455.39 | 7,891 | 1,141 | -12,818 | Upgrade
|
Net Cash Flow | -27,143 | -55,660 | -80,694 | -46,228 | 133,827 | Upgrade
|
Free Cash Flow | -85,452 | -84,560 | 61,158 | 23,658 | -46,902 | Upgrade
|
Free Cash Flow Growth | - | - | 158.51% | - | - | Upgrade
|
Free Cash Flow Margin | -5.09% | -5.20% | 3.57% | 1.54% | -3.12% | Upgrade
|
Free Cash Flow Per Share | -7487.13 | -7408.97 | 5358.56 | 4681.52 | -4109.46 | Upgrade
|
Cash Interest Paid | 38,139 | 24,080 | 19,378 | 13,546 | 9,727 | Upgrade
|
Cash Income Tax Paid | 2,468 | 19,033 | 37,349 | 18,867 | 8,983 | Upgrade
|
Levered Free Cash Flow | -119,077 | -166,642 | 52,929 | -10,238 | -57,365 | Upgrade
|
Unlevered Free Cash Flow | -93,803 | -148,840 | 64,424 | -2,425 | -50,894 | Upgrade
|
Change in Net Working Capital | 153,267 | 120,932 | -43,575 | -19,057 | 29,830 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.